Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial
Open Access
- 8 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (2), 237-243
- https://doi.org/10.1093/infdis/jir723
Abstract
Background. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post–oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. Results. In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. Conclusions. Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. Clinical Trials Registration. NCT01056705.Keywords
This publication has 8 references indexed in Scilit:
- Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strainsExpert Review of Vaccines, 2011
- Implications of a Circulating Vaccine-Derived Poliovirus in NigeriaThe New England Journal of Medicine, 2010
- Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradicationVaccine, 2009
- Technology transfer of Sabin-IPV to new developing country marketsBiologicals, 2006
- Development of inactivated poliovirus vaccine derived from Sabin strainsBiologicals, 2006
- 1,25‐Dihydroxyvitamin D3 Enhances Systemic and Mucosal Immune Responses to Inactivated Poliovirus Vaccine in MiceThe Journal of Infectious Diseases, 2006
- Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strainsVaccine, 1999
- Inactivation of poliovirus with β-propiolactoneJournal of Biological Standardization, 1986